Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
| Image |  |
|---|---|
| Description | scientific article published on 30 April 2017 |
| Author/s | |
| Publication date | April 30, 2017 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |